PTGS2 and renal carcinoma: Next, we examined how prevalent PGE2 and COX-2 upregulation was post-CTX treatment across multiple murine cancer cell lines of different tissue origins, covering breast, colorectal, melanoma, pancreatic, lung and renal cancer.